Conversely, some biomarkers, such as the soluble suppression of tumorigenicity 2 (sST2), galectin-3 (Gal-3), and N-terminal portion of the B-type natriuretic peptide (NT-proBNP), have been related with myocardial fibrosis, inflammation, and congestion, which are affecting the prognosis in HF patients (4–6). This evidence concerns the gene NPPB and hydrops fetalis.